Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.New research has suggested that treatment with Fuzeon, a drug developed by Roche AG and US biotech Trimeris, gives HIV patients facing resistance their best chance of achieving undetectable viral load – the optimal treatment goal for all people living with HIV.
Subscribe to our email newsletter
Dr Mike Youle from the Royal Free Hospital, London said: “We are seeing a consistent Fuzeon effect with these new drugs and I believe these data must change the way we manage triple class experienced patients facing HIV resistance and failing to reach undetectable viral load.”
When combined with the novel HIV medication, tipranavir, an impressive 70% of Fuzeon naive patients achieved a ten-fold reduction in their viral load and displayed double the amount of immune cell count1 compared to patients receiving tipranavir without Fuzeon.
This adds to the growing body of evidence showing that when used in various drug combinations Fuzeon can almost double the number of patients achieving an undetectable viral load.
Surprisingly, even in the face of such evidence, a reported 75% of doctors recently surveyed underestimated the benefits Fuzeon could provide.